NL-OMON28819招募中不适用
Transarterial Chemoembolization with Drug-Eluting Beads (standard arm) versus Stereotactic Body Radiation Therapy (experimental arm) for hepatocellular carcinoma: A multicenter randomized phase II trialThe TRENDY trial”
Erasmus MCDepartment of Radiotherapy0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •In order to be eligible to participate in this study, a subject must be discussed in a multidisciplinary liver tumor board and should meet all of the following criteria:
- •Patients diagnosed with HCC (follow the diagnostic algorithm recommended by the
- •EASL–EORTC Clinical Practice Guidelines 2012) [1].
- •Barcelona Clinic Liver Cancer Stage System class A-B
- •One tumor of maximum diameter ≤ 6 cm measured in all 3 axes. A maximum of two satellite nodules around the main tumor are accepted. Satellite nodules should fulfill the following criteria: Distance from the main tumor to the inner border of the nodules should be < 1 cm, maximum diameter of each nodule should be ≤ 5 mm, maximum diameter of the main tumor together with the nodules should be ≤ 6 cm in all 3 axes.
- •Measurable disease on CT/MRI-scan, according to mRECIST criteria for HCC within 6 weeks prior to randomization [44].
- •Tumor visibility on CT
- •Child-Pugh A cirrhosis
- •Age ≥ 18 years
- •ECOG performance status 0-1
- •Albumin> 28 g/l, bilirubin < 50 µmol/l, INR < 2.3, AST/ALT < 5 times ULN, within 6 weeks prior to randomization
- •Platelets ≥ 50x10E9/ l, neutrophils > 0.75x10E9/l, Hb > 6 mmol/l, within 6 weeks prior to randomization
- •Written informed consent
- •Willing and able to comply to the follow-up schedule
- •Planned to start treatment within 6 weeks from randomization.
排除标准
- •A potential subject who meets any of the following criteria will be excluded from participation in this study:
- •Eligibility for resection or RFA
- •More than one tumor in the liver
- •Any signs of acute viral or non-viral hepatitis
- •Encephalopathy
- •Vascular tumor invasion (contact with the vessel will not be considered contraindication).
- •Previous radiotherapy to the liver
- •Known current pregnancy
- •Distance from the tumor to the esophagus, stomach, duodenum, small bowel or large bowel < 2 cm on CT or on MRI. Uncontrolled portal hypertension (high bleeding risk). If gastroscopy has been performed, untreated esophageal varices grade III or IV.
研究者
相似试验
进行中(未招募)
不适用
DEBDOX for liver metastases in breast carcinomaEUCTR2012-000973-22-NL
尚未招募
2 期
Transarterial Chemoembolization with Drug-Eluting Beads Loaded with Doxorubicin for the Treatment of Metastatic Breast Cancer to the Liver: a pilot studyliver metastases breast cancer10027476NL-OMON37702Antoni van Leeuwenhoek Ziekenhuis10
招募中
2 期
Transarterial Chemoembolization with Drug-Eluting Beads (standard arm) versus Stereotactic Body Radiation Therapy (experimental arm) for hepatocellular carcinoma: A multicenter randomized phase II trial *The TRENDY trial*hepatocellular carcinomaNL-OMON44103Erasmus MC, Universitair Medisch Centrum Rotterdam64
已完成
不适用
The Impact of Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinoma: A Single Center ExperienceHepatocellular carcinomaBCLC stage CBCLC stage CTACETransarterial ChemoembolizationHepatocellular carcinomaTCTR20150221001Rajavithi Hospital44
已完成
2 期
Phase II trial of Transarterial Chemoembolization using Drug-eluting bead for advanced HCC refractory to Lipiodol-TACEadvanced hepatocellular carcinomaJPRN-UMIN000015463Clinical Research Group of the Japanese Society for Transcatheter Hepatic Arterial Embolization24
